Efficacy
-
{
- All
- News
- Videos
-
Govt Proposes 12-Month Minimum Shelf-Life Mandate For Imported Drugs
The government has proposed easing the residual shelf-life requirement for imported drugs by replacing the existing norm of more than 60 per cent remaining shelf life with a minimum shelf life of 12 months at the time of import.
-
Do Current Vaccines Work On Omicron? Top WHO Expert's Reply
Preliminary evidence on Omicron suggests "higher transmissibility", WHO Regional Director for South East Asia Dr Poonam Khetrapal told NDTV today, adding that "regardless of the change in severity, increase in cases alone may pose overwhelming demand
-
Moderna CEO Says World May Need New Vaccines To Fight Omicron
Existing Covid-19 inoculations will struggle against the fast-spreading Omicron variant, the head of vaccine manufacturer Moderna warned Tuesday, as countries ramp up vaccination programmes and impose further restrictions to curb growing concern.
-
Omicron: Are New Vaccines Needed? What Vaccine-Makers Say
'Omicron', the new Covid variant first found in South Africa, has already caused global concern leading to countries shutting their borders, new travel guidelines, sell-offs in financial markets, and a bleak future for expected post-pandemic recovery
-
'Omicron' May Be A Wake-Up Call: WHO's Dr Soumya Swaminathan
Ms Swaminathan added that this variant could be more transmissible than Delta, though one can't say anything authoritatively yet. We will know more about the strain in a few days, she said.
-
Vaccine Efficacy Against New Covid Variant Under Examination: Scientist
Vaccines that have been directed towards the spike protein of the virus may find difficulty in mounting adequate immunity against the mutated version because of the structural changes that have been reported in the viral genome, according to WHO.
-
Both Doses Of Vaccine Give 98% Protection From Death Due To Covid: Centre
Both the doses of Covid vaccine provide around 98 per cent protection from death due to the disease, while one dose gives nearly 92 per cent shield, the government said today citing a study conducted on police personnel in Punjab.
-
"No Scientific Data": Dr VK Paul On Vaccine's Efficacy On Delta Plus Covid Variant
Covid Task Force chief VK Paul today said it will be unfair to put a date for any Covid wave as the behaviour of the virus is unpredictable and a disciplined and effective pandemic response can help India get away from any significant outbreak.
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Bharat Biotech Says Covaxin Shows 78% Efficacy Against Mild To Severe COVID-19
Bharat Biotech on Wednesday said its coronavirus vaccine Covaxin has shown efficacy of 78 per cent against mild, moderate and severe cases of COVID-19, as per Phase III interim analysis results.
-
China Mulls Mixing Different COVID-19 Vaccines To Improve Efficacy Of Jabs
China is considering the mixing of different Covid-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert has told a conference.
-
Covaxin Maker Says It's 81% Effective. What Next? A 7-Point Guide
Today, Bharat Biotech, the company that makes Covaxin, said that new data shows it is 81 per cent effective in protecting against COVID-19. This is interim analysis of Phase 3 of its trial. What does this data mean?
-
Covaxin 81% Effective, Works Against UK Variant, Claims Bharat Biotech
Covaxin is 81 per cent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed a "first interim analysis" of Phase III trial results for a vaccine cleared in January amid concerns over safety and efficacy.
-
Health Minister Slams Congress MP For Doubting Vaccine Efficacy, Safety
Union Health Minister Dr Harsh Vardhan today slammed Congress Member of Parliament Manish Tewari for raising questions over the safety and efficacy of the COVID-19 vaccines being administered as India launched its nationwide vaccination drive.
-
"Vaccine More Effective If Longer Gap Between Doses": Serum To NDTV
The efficacy of the Covishield vaccine goes up if the gap between two doses is more than 28 days, a top scientist at Adar Poonawalla's Serum Institute of India (SII) said today, a day before the launch of India's Covid vaccination drive.
-
Govt Proposes 12-Month Minimum Shelf-Life Mandate For Imported Drugs
The government has proposed easing the residual shelf-life requirement for imported drugs by replacing the existing norm of more than 60 per cent remaining shelf life with a minimum shelf life of 12 months at the time of import.
-
Do Current Vaccines Work On Omicron? Top WHO Expert's Reply
Preliminary evidence on Omicron suggests "higher transmissibility", WHO Regional Director for South East Asia Dr Poonam Khetrapal told NDTV today, adding that "regardless of the change in severity, increase in cases alone may pose overwhelming demand
-
Moderna CEO Says World May Need New Vaccines To Fight Omicron
Existing Covid-19 inoculations will struggle against the fast-spreading Omicron variant, the head of vaccine manufacturer Moderna warned Tuesday, as countries ramp up vaccination programmes and impose further restrictions to curb growing concern.
-
Omicron: Are New Vaccines Needed? What Vaccine-Makers Say
'Omicron', the new Covid variant first found in South Africa, has already caused global concern leading to countries shutting their borders, new travel guidelines, sell-offs in financial markets, and a bleak future for expected post-pandemic recovery
-
'Omicron' May Be A Wake-Up Call: WHO's Dr Soumya Swaminathan
Ms Swaminathan added that this variant could be more transmissible than Delta, though one can't say anything authoritatively yet. We will know more about the strain in a few days, she said.
-
Vaccine Efficacy Against New Covid Variant Under Examination: Scientist
Vaccines that have been directed towards the spike protein of the virus may find difficulty in mounting adequate immunity against the mutated version because of the structural changes that have been reported in the viral genome, according to WHO.
-
Both Doses Of Vaccine Give 98% Protection From Death Due To Covid: Centre
Both the doses of Covid vaccine provide around 98 per cent protection from death due to the disease, while one dose gives nearly 92 per cent shield, the government said today citing a study conducted on police personnel in Punjab.
-
"No Scientific Data": Dr VK Paul On Vaccine's Efficacy On Delta Plus Covid Variant
Covid Task Force chief VK Paul today said it will be unfair to put a date for any Covid wave as the behaviour of the virus is unpredictable and a disciplined and effective pandemic response can help India get away from any significant outbreak.
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Bharat Biotech Says Covaxin Shows 78% Efficacy Against Mild To Severe COVID-19
Bharat Biotech on Wednesday said its coronavirus vaccine Covaxin has shown efficacy of 78 per cent against mild, moderate and severe cases of COVID-19, as per Phase III interim analysis results.
-
China Mulls Mixing Different COVID-19 Vaccines To Improve Efficacy Of Jabs
China is considering the mixing of different Covid-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert has told a conference.
-
Covaxin Maker Says It's 81% Effective. What Next? A 7-Point Guide
Today, Bharat Biotech, the company that makes Covaxin, said that new data shows it is 81 per cent effective in protecting against COVID-19. This is interim analysis of Phase 3 of its trial. What does this data mean?
-
Covaxin 81% Effective, Works Against UK Variant, Claims Bharat Biotech
Covaxin is 81 per cent effective in preventing Covid and can work against the UK variant of the virus, Bharat Biotech said Wednesday as it revealed a "first interim analysis" of Phase III trial results for a vaccine cleared in January amid concerns over safety and efficacy.
-
Health Minister Slams Congress MP For Doubting Vaccine Efficacy, Safety
Union Health Minister Dr Harsh Vardhan today slammed Congress Member of Parliament Manish Tewari for raising questions over the safety and efficacy of the COVID-19 vaccines being administered as India launched its nationwide vaccination drive.
-
"Vaccine More Effective If Longer Gap Between Doses": Serum To NDTV
The efficacy of the Covishield vaccine goes up if the gap between two doses is more than 28 days, a top scientist at Adar Poonawalla's Serum Institute of India (SII) said today, a day before the launch of India's Covid vaccination drive.
